{"entity":{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","aka":["FONTANA"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT05797168 as recruiting, last updated 2026-10-05. Enrolment is 622 planned participants, an estimate. Interventions: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab. Primary measures include Number of participants with adverse events/serious adverse events; The number of participants with dose limiting toxicity(DLT), as defined in the protocol. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05797168","url":"https://clinicaltrials.gov/study/NCT05797168"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["azd5335","saruparib","bevacizumab","carboplatin","palacaparib","pembrolizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05797168","phase":"1/2","setting":"A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors","sponsor":"AstraZeneca","participation":[{"nct":"NCT05797168","source":"https://clinicaltrials.gov/study/NCT05797168","fetchedAt":"2026-10-07T16:53:55.392Z","studySha256":"cd006fa4348a5c8d6253b2f858b2fb71f023a47085dfdafadfcc8d92faa2bf98","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-05","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":622,"enrolmentType":"ESTIMATED","siteCount":60,"recruitingSiteCount":55,"countries":["Australia","Canada","China","Germany","Israel","Japan","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-06-05","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05797168/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}